Trovagene Q4 Revenues up 41 Percent as Net Loss Widens | GenomeWeb

This story has been updated to provide comments from Trovagene's management made during a conference call with investors.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Thursday that its fourth quarter revenues rose 41 percent year over year.

The liquid biopsy MDx developer said its revenues rose to $79,000 for the three months ended Dec. 31, 2015, up from $56,000 in Q4 2014. However, the revenues significantly missed analysts' estimates of $100,000 for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.